| Literature DB >> 31511971 |
Bo-Wen Lei1,2, Jia-Qian Hu1,2, Peng-Cheng Yu1,2, Yu-Long Wang1,2, Wen-Jun Wei1,2, Ji Zhu2,3,4, Xiao Shi1,2, Ning Qu1,2, Zhong-Wu Lu5,6, Qing-Hai Ji7,8.
Abstract
PURPOSE: The role of lymph node ratio (LNR, ratio of metastatic to examined nodes) in the staging of multiple human malignancies has been reported. We aim to evaluate its value in salivary gland cancer (SGC).Entities:
Keywords: Lymph node ratio; Prognosis; Radiotherapy; Salivary gland cancer; TNM staging
Mesh:
Year: 2019 PMID: 31511971 PMCID: PMC6858905 DOI: 10.1007/s00405-019-05597-0
Source DB: PubMed Journal: Eur Arch Otorhinolaryngol ISSN: 0937-4477 Impact factor: 2.503
Characteristics of SEER patients with lymph node (LN) positive salivary gland cancer
| Categorical variables | No. of patients ( | % |
|---|---|---|
| Race | ||
| White | 1042 | 86.1 |
| Black | 71 | 5.9 |
| Other | 97 | 8.0 |
| Gender | ||
| Male | 843 | 69.7 |
| Female | 367 | 30.3 |
| Year of diagnosis | ||
| 1988–1994 | 103 | 8.5 |
| 1995–2001 | 290 | 24.0 |
| 2002–2008 | 817 | 67.5 |
| Primary site | ||
| Parotid | 968 | 80.0 |
| Submandibular | 201 | 16.6 |
| Sublingual | 9 | 0.7 |
| Others | 32 | 2.6 |
| Histologic subtype | ||
| Squamous cell carcinoma | 289 | 19.8 |
| Adenocarcinoma | 187 | 14.6 |
| Adenoid cystic carcinoma | 92 | 7.6 |
| Mucoepidermoid carcinoma | 234 | 19.3 |
| Other | 408 | 38.6 |
| Grade | ||
| I | 35 | 2.9 |
| II | 185 | 15.3 |
| III | 499 | 41.2 |
| IV | 237 | 19.6 |
| Unknown | 254 | 21.0 |
| Surgery and radiation | ||
| Both | 930 | 76.9 |
| No | 280 | 23.1 |
| T staging | ||
| T1 + T2 | 355 | 29.3 |
| T3 + T4 | 744 | 61.5 |
| Tx | 111 | 9.2 |
| N staging | ||
| N1 | 456 | 37.7 |
| N2 | 725 | 59.9 |
| N3 | 29 | 2.4 |
| M staging | ||
| M0 | 1124 | 92.9 |
| M1 | 48 | 4.0 |
| Mx | 38 | 3.1 |
| Continuos variables | Median (range) | |
| Age | 65 years (6–100) | |
| No. of LN examined | 16 (1–90) | |
| No. of positive LNs | 2 (1–83) | |
| Lymph node ratio | 0.31 (0.01–1.00) | |
Prognostic factors of SEER cause-specific survival among SEER patients with lymph node (LN) involved salivary gland cancer
| Variables | Hazard ratio (95% CIs) | |
|---|---|---|
| Primary site | ||
| Parotid (reference) | ||
| Submandibular | 1.413 (1.126–1.773) | 0.002 |
| Sublingual | 1.230 (0.398–3.919) | 0.702 |
| Others | 0.684 (0.337–1.386) | 0.291 |
| T classification | ||
| T1 + T2 (reference) | ||
| T3 + T4 | 1.870 (1.474–2.373) | < 0.001 |
| Tx | 0.937 (0.613–1.431) | 0.762 |
| N classification | ||
| N1 (reference) | ||
| N2 | 1.421 (1.130–1.787) | 0.003 |
| N3 | 2.099 (1.266–3.479) | 0.004 |
| M classification | ||
| M0 (reference) | ||
| M1 | 5.229 (3.604–7.586) | < 0.001 |
| Mx | 1.452 (0.846–2.494) | 0.176 |
| No. of LNs examined | 1.012 (1.007–1.017) | < 0.001 |
| Lymph node ratio(LNR) | 2.208 (1.671–2.918) | < 0.001 |
| Age | 1.017 (1.007–1.017) | < 0.001 |
Univariate and multivariate analysis of categorical and continuous LNR with SEER cause-specific survival (CSS) of SEER salivary gland cancer pN+patients
| LNR classification | Number | 5-year | Log-rank | Multivariate analysisa | ||
|---|---|---|---|---|---|---|
| CSS(%) | HR (95% CI) | AIC | ||||
| Cutpoints 0.17/0.55 | 32.149 | 0.695 | 5626.36 | |||
| R1: 0–0.17 | 430 | 57.2 | (< 0.001) | Reference | ||
| R2: 0.17–0.55 | 380 | 52.9 | 1.284 (0.993–1.663) | |||
| R3: > 0.55 | 400 | 39.9 | 1.986 (1.560–2.528) | |||
| Cutpoints 0.17/0.56 | 33.062 | 0.696 | 5625.15 | |||
| R1: 0–0.17 | 430 | 57.2 | (< 0.001) | Reference | ||
| R2: 0.17–0.56 | 384 | 53.1 | 1.276 (0.986–1.650) | |||
| R3: > 0.56 | 396 | 39.7 | 2.008 (1.578–2.557) | |||
| Continuous LNR | 2.208 (1.671–2.918) | 0.692 | 5627.78 | |||
aThe multivariate analysis was adjusted using the same Cox regression model at Table 2
Fig. 1Kaplan–Meier survival estimates according to pN classification and R classification: cause-specific survival (CSS) of the SEER set with different pN classification (a) and R classification (b); disease-free survival (DFS) of the FUSCC set with different pN classification (c) and R classification (d); disease-specific survival (DSS) of the FUSCC set with different pN classification (e) and R classification (f); compared with the overlap of the pN classification survival curves, R classification showed better discriminatory ability for salivary gland cancer survival
Different staging systems for SEER cause-specific survival (CSS) of SEER patients with salivary gland cancer
| Staging system | Patients no.a | 5-year CSS survival (%) | Log-rank | Multivariate analysisb | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | AIC | |||||
| N classification | 755.366 | 0.830 | 11,304.72 | |||
| N0 | 3052 | 88.6 | (< 0.001) | Reference | ||
| N1 | 456 | 66.0 | 1.866 (1.500–2.322) | |||
| N2 | 725 | 40.2 | 2.643 (2.197–3.179) | |||
| N3 | 29 | 43.3 | 4.381 (2.685–7.149) | |||
| R classification | 722.815 | 0.832 | 11,287.32 | |||
| R0 | 3052 | 88.6 | (< 0.001) | Reference | ||
| R1: 0–0.17 | 430 | 57.2 | 1.703 (1.363–2.127) | |||
| R2: 0.17–0.56 | 384 | 53.1 | 2.215 (1.789–2.742) | |||
| R3: > 0.56 | 396 | 39.7 | 3.348 (2.738–4.095) | |||
| TNM staging | 964.290 | 0.823 | 10,583.18 | |||
| I | 1069 | 96.6 | (< 0.001) | Reference | ||
| II | 753 | 93.2 | 1.788 (1.163–2.749) | |||
| III | 908 | 79.1 | 4.601 (3.188–6.640) | |||
| IVA | 990 | 52.5 | 8.457 (5.868–12.189) | |||
| IVB | 131 | 42.3 | 12.999 (8.477–19.934) | |||
| IVC | 93 | 17.6 | 26.937 (17.476–41.518) | |||
| TRM stagingc | 1000.667 | 0.828 | 10,551.61 | |||
| I | 1069 | 96.6 | (< 0.001) | |||
| II | 753 | 93.2 | 1.784 (1.161–2.743) | |||
| III | 890 | 77.1 | 4.428 (3.066–6.395) | |||
| IVA | 725 | 61.1 | 7.037 (4.859–10.191) | |||
| IVB | 414 | 40.6 | 12.397 (8.519–18.041) | |||
| IVC | 93 | 17.6 | 26.557 (17.246–40.895) | |||
| TNM + R staging | 0.830 | 10,536.22 | ||||
aFor N classification and R classification, a total of 4262 patients with the number of lymph nodes examined were analyzed. For TNM staging, TRM staging, TNM + R staging, a total of 3944 patients were enrolled for sufficient TNM staging information
bN classification and R classification were adjusted for primary site, histologic type, histologic grade, site-directed surgery, radiotherapy, the number of lymph nodes examined, T classification, M classification and age of the SEER patients (variables identified in Supplement Table 2). TNM staging, TRM staging and TNM + R staging (TNM staging and R classification as two variables enrolled in the Cox regression together) were adjusted for primary site, histologic type, histological grade, site directed surgery, radiation, the number of lymph nodes examined and age of the SEER patients (variables identified in Supplement Table 3)
cTRM staging system was defined as I: T1-R0-M0; II: T2-R0-M0; III: T3-R0-M0, T1-R1-M0, T2-R1-M0, T3-R1-M0; IVA: T4a-R0-M0, T4a-R1-M0, T1-R2-M0, T2-R2-M0, T3-R2-M0, T4a-R2-M0; IVB: T4b-Any R-M0, Any T-R3-M0; IVC: any T-Any R-M
Validation of R classification system for predicting salivary gland cancer disease free survival (DFS) and disease specific survival (DSS) in FDSCC patients with neck dissection
| Staging | Case No | 5-year DFS | Log-rank | Multivariate analysis of DFSa | 5-year DSS | Log-rank | Multivariate analysis of DSSb | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | AIC | HR (95% CIs) | AIC | ||||||||
| N classification | 25.096 | 0.73 | 400.009 | 10.799 | 0.734 | 106.753 | |||||
| N0 | 88 | 69.2 | (< 0.001) | Reference | 92.3 | (0.005) | Reference | ||||
| N1 | 14 | 71.4 | 0.541 (0.124–2.358) | 85.7 | 1.914(0.199–18.460) | ||||||
| N2 | 52 | 30.9 | 3.235 (1.746–5.995) | 66.9 | 6.552(1.764–24.330) | ||||||
| N3 | 0 | ||||||||||
| R classification | 43.897 | 0.72 | 397.649 | 37.986 | 0.796 | 98.113 | |||||
| R0 | 88 | 69.2 | (< 0.001) | Reference | 92.3 | (< 0.001) | Reference | ||||
| R1: 0–0.17 | 29 | 63.3 | 1.249 (0.535–2.918) | 90.0 | 1.027(0.107–9.891) | ||||||
| R2: 0.17–0.56 | 21 | 34.6 | 2.527 (1.137–5.616) | 71.4 | 4.715(0.949–23.429) | ||||||
| R3: > 0.56 | 16 | 0 | 7.007 (3.239–15.156) | 0 | 21.677(5.285–88.916) | ||||||
| TNM staging c | 0.663 | 412.414 | 0.736 | 110.621 | |||||||
| TNM + R stagingd | 0.728 | 402.68 | 0.856 | 103.149 | |||||||
aN classification and R classification were adjusted for extraparenchymal invasion
bN classification or R classification was the only prognostic variable kept in the Cox model
cTNM staging was the only variable in the Cox regression model
dBoth TNM staging and R classification were variables in the Cox regression model
Fig. 2Survival differences of individual R classification FUSCC patients with and without postoperative radiotherapy (Rx): disease-free survival (a) and disease-specific survival (b)